(Q24246232)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16625629%20AND%20SRC:MED&resulttype=core&format=json

19 January 2020

0 references

1 reference

title

Risperidone versus olanzapine for schizophrenia (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16625629%20AND%20SRC:MED&resulttype=core&format=json

19 January 2020

0 references

1 reference

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16625629%20AND%20SRC:MED&resulttype=core&format=json

19 January 2020

author name string

P Hosalli

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16625629%20AND%20SRC:MED&resulttype=core&format=json

19 January 2020

S Stroup

series ordinal

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16625629%20AND%20SRC:MED&resulttype=core&format=json

19 January 2020

publication date

19 April 2006

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16625629%20AND%20SRC:MED&resulttype=core&format=json

Cochrane Database of Systematic Reviews

19 January 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16625629%20AND%20SRC:MED&resulttype=core&format=json

19 January 2020

issue

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16625629%20AND%20SRC:MED&resulttype=core&format=json

19 January 2020

page(s)

CD005237

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16625629%20AND%20SRC:MED&resulttype=core&format=json

Effect of divalproex combined with olanzapine or risperidone in patients with an acute exacerbation of schizophrenia

19 January 2020

cites work

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005237.PUB2

Adjunctive divalproex and hostility among patients with schizophrenia receiving olanzapine or risperidone

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005237.PUB2

Effectiveness of antipsychotic drugs in patients with chronic schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005237.PUB2

Schizophrenia, VI: Treatments

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005237.PUB2

The National Institute of Mental Health Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) project: schizophrenia trial design and protocol development

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005237.PUB2

The Efficacy of High-Dose Olanzapine Versus Clozapine in Treatment-Resistant Schizophrenia: A Double-Blind Crossover Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005237.PUB2

A randomized double-blind study of risperidone and olanzapine in the treatment of schizophrenia or schizoaffective disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005237.PUB2

Changes in cognitive functioning with risperidone and olanzapine treatment: a large-scale, double-blind, randomized study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005237.PUB2

Olanzapine vs risperidone in the management of schizophrenia: a randomized double-blind trial in Australia and New Zealand

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005237.PUB2

Comparative effects of risperidone and olanzapine on cognition in elderly patients with schizophrenia or schizoaffective disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005237.PUB2

Source monitoring improvement in patients with schizophrenia receiving antipsychotic medications

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005237.PUB2

Procedural learning in schizophrenia after 6 months of double-blind treatment with olanzapine, risperidone, and haloperidol

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005237.PUB2

The impact upon extra-pyramidal side effects, clinical symptoms and quality of life of a switch from conventional to atypical antipsychotics (risperidone or olanzapine) in elderly patients with schizophrenia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005237.PUB2

The effects of olanzapine, risperidone, and haloperidol on plasma prolactin levels in patients with schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005237.PUB2

Olanzapine versus risperidone. A prospective comparison of clinical and economic outcomes in schizophrenia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005237.PUB2

Time to study discontinuation, relapse, and compliance with atypical or conventional antipsychotics in schizophrenia and related disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005237.PUB2

The course of depressive symptoms in predicting relapse in schizophrenia: a double-blind, randomized comparison of olanzapine and risperidone

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005237.PUB2

Double-blind comparison of olanzapine versus risperidone in the treatment of schizophrenia and other psychotic disorders.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005237.PUB2

Neurocognitive effects of clozapine, olanzapine, risperidone, and haloperidol in patients with chronic schizophrenia or schizoaffective disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005237.PUB2

Effects of clozapine, olanzapine, risperidone, and haloperidol on hostility among patients with schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005237.PUB2

Changes in glucose and cholesterol levels in patients with schizophrenia treated with typical or atypical antipsychotics

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005237.PUB2

Overt aggression and psychotic symptoms in patients with schizophrenia treated with clozapine, olanzapine, risperidone, or haloperidol

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005237.PUB2

Clozapine, olanzapine, risperidone, and haloperidol in the treatment of patients with chronic schizophrenia and schizoaffective disorder.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005237.PUB2

Effects of neuroleptic medications on speech disorganization in schizophrenia: biasing associative networks towards meaning

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005237.PUB2

Olanzapine, risperidone and haloperidol in the treatment of adolescent patients with schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005237.PUB2

Placebo-controlled trial of D-cycloserine added to conventional neuroleptics, olanzapine, or risperidone in schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005237.PUB2

High-dose glycine added to olanzapine and risperidone for the treatment of schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005237.PUB2

Cost-effectiveness of risperidone, olanzapine, and conventional antipsychotic medications

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005237.PUB2

Longitudinal effect of olanzapine on fasting serum lipids: a randomized, prospective, 4-month study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005237.PUB2

A comparison of two novel antipsychotics in first episode non-affective psychosis: one-year outcome on symptoms, motor side effects and cognition

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005237.PUB2

Elevation of prolactin levels by atypical antipsychotics

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005237.PUB2

Minimum effective doses of haloperidol for the treatment of first psychotic episode: a comparative study with risperidone and olanzapine

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005237.PUB2

Absence of effect of olanzapine on primary polydipsia: results of a double-blind, randomized study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005237.PUB2

A randomized evaluation of the effects of six antipsychotic agents on QTc, in the absence and presence of metabolic inhibition

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005237.PUB2

Measurement of simple reaction time in antipsychotic treatment of patients with schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005237.PUB2

Dropout rates with olanzapine or risperidone: a multi-centre observational study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005237.PUB2

A Pilot Study of Risperidone, Olanzapine, and Haloperidol in Psychotic Youth: A Double-Blind, Randomized, 8-Week Trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005237.PUB2

Symptom response and side-effects of olanzapine and risperidone in young adults with recent onset schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005237.PUB2

Negative symptoms in schizophrenia. Definition and reliability

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005237.PUB2

Survey on schizophrenia treatment in Mexico: perception and antipsychotic prescription patterns

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005237.PUB2

Ziprasidone for schizophrenia and severe mental illness

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005237.PUB2

A rating scale for drug-induced akathisia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005237.PUB2

Statistics notes. Trials randomised in clusters

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005237.PUB2

New dimensions in the pharmacologic treatment of schizophrenia and related psychoses

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005237.PUB2

Olanzapine compared with chlorpromazine in treatment-resistant schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005237.PUB2

The unit of analysis error in studies about physicians' patient care behavior

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005237.PUB2

Issues in the meta-analysis of cluster randomized trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005237.PUB2

Olanzapine for schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005237.PUB2

Bias in meta-analysis detected by a simple, graphical test

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005237.PUB2

Aripiprazole for schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005237.PUB2

Zotepine for schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005237.PUB2

Components of variance and intraclass correlations for the design of community-based surveys and intervention studies: data from the Health Survey for England 1994.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005237.PUB2

A rating scale for depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005237.PUB2

Measuring inconsistency in meta-analyses

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005237.PUB2

Risperidone versus typical antipsychotic medication for schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005237.PUB2

Schizophrenia: manifestations, incidence and course in different cultures. A World Health Organization ten-country study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005237.PUB2

Assessing the quality of reports of randomized clinical trials: is blinding necessary?

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005237.PUB2

Haloperidol versus placebo for schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005237.PUB2

Systematic reviews in health care: Assessing the quality of controlled clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005237.PUB2

Unpublished rating scales: a major source of bias in randomised controlled trials of treatments for schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005237.PUB2

The CONSORT statement: revised recommendations for improving the quality of reports of parallel-group randomized trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005237.PUB2

Amisulpride for schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005237.PUB2

Patient characteristics and prescription patterns of atypical antipsychotics among patients with schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005237.PUB2

Empirical evidence of bias. Dimensions of methodological quality associated with estimates of treatment effects in controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005237.PUB2

Quetiapine for schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005237.PUB2

Chlorpromazine versus placebo for schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005237.PUB2

Olanzapine versus haloperidol in the treatment of schizophrenia and schizoaffective and schizophreniform disorders: results of an international collaborative trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005237.PUB2

Dropout rates in randomised antipsychotic drug trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005237.PUB2

Neuropsychological change in early phase schizophrenia during 12 months of treatment with olanzapine, risperidone, or haloperidol. The Canadian Collaborative Group for research in schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005237.PUB2

7 January 2021

Neuroendocrine responsivities of the pituitary dopamine system in male schizophrenic patients during treatment with clozapine, olanzapine, risperidone, sulpiride, or haloperidol

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005237.PUB2

7 January 2021

https://api.crossref.org/works/10.1002%2F14651858.CD005237.PUB2

1 reference

7 January 2021

Nithsdale schizophrenia surveys. 17. Fifteen year review

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005237.PUB2

7 January 2021

Retrospective analysis of risk factors in patients with treatment-emergent diabetes during clinical trials of antipsychotic medications.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005237.PUB2

7 January 2021

Strategies for switching from conventional antipsychotic drugs or risperidone to olanzapine.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005237.PUB2

7 January 2021

Analysis of the QTc interval during olanzapine treatment of patients with schizophrenia and related psychosis.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005237.PUB2

7 January 2021

Factors influencing acute weight change in patients with schizophrenia treated with olanzapine, haloperidol, or risperidone

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005237.PUB2

7 January 2021

Obsessive-compulsive symptoms during treatment with olanzapine and risperidone: a prospective study of 113 patients with recent-onset schizophrenia or related disorders.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005237.PUB2

7 January 2021

Serum leptin and triglyceride levels in patients on treatment with atypical antipsychotics.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005237.PUB2

7 January 2021

Comparison of risperidone and olanzapine in the control of negative symptoms of chronic schizophrenia and related psychotic disorders in patients aged 50 to 65 years.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005237.PUB2

7 January 2021

Prolactin levels in schizophrenia and schizoaffective disorder patients treated with clozapine, olanzapine, risperidone, or haloperidol.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005237.PUB2

7 January 2021

Adherence to conventional and atypical antipsychotics after hospital discharge.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005237.PUB2

7 January 2021

Effects of changing from typical to atypical antipsychotic drugs on subjective sleep quality in patients with schizophrenia in a Japanese population.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005237.PUB2

7 January 2021

10.1002/14651858.CD005237.PUB2

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16625629%20AND%20SRC:MED&resulttype=core&format=json

release_bzlcrmqr4jdafnvterplbsvdzm

19 January 2020

Fatcat ID

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/bzlcrmqr4jdafnvterplbsvdzm

24 November 2022

mapped directly with Wikidata item

1 reference